Fotivda

Chemical Nametivozanib
Dosage FormCapsule (oral; 0.89 mg, 1.34 mg)
Drug ClassKinase inhibitors
SystemUrinary
CompanyAVEO Pharmaceuticals
Approval Year2021

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies
Last updated on 3/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fotivda (tivozanib) Prescribing Information.2021AVEO Pharmaceuticals Inc., Boston, MA
Document TitleYearSource
Assessment report: Fotivda. 2017EMA
Document TitleYearSource
Targeted therapy for metastatic renal cell carcinoma. 2020Cochrane Database of Systematic Reviews